TW200716094A - Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor - Google Patents

Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor

Info

Publication number: TW200716094A
Authority: TW; Taiwan
Prior art keywords: methods; pharmaceutical compositions; aromatase inhibitor; combination; phenyl
Prior art date: 2005-04-25

Application number

TW095114529A

Other languages

English (en)

Chinese (zh)

Inventor

Madelyn Curto

Melanie Sisson

Andrew George Lee

David Duane Thompson

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-25

Filing date

2006-04-24

Publication date

2007-05-01

2006-04-24 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2007-05-01 Publication of TW200716094A publication Critical patent/TW200716094A/zh

Links

229940122815 Aromatase inhibitor Drugs 0.000 title abstract 3
239000003886 aromatase inhibitor Substances 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
229940095743 selective estrogen receptor modulator Drugs 0.000 title 1
239000000333 selective estrogen receptor modulator Substances 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 3
239000000651 prodrug Substances 0.000 abstract 2
229940002612 prodrug Drugs 0.000 abstract 2
CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 abstract 1
GGPPBTSXFROGAE-UHFFFAOYSA-N 4-[(4-bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile Chemical compound C1=CC(Br)=CC=C1CN(N1C=NN=C1)C1=CC=C(C#N)C=C1 GGPPBTSXFROGAE-UHFFFAOYSA-N 0.000 abstract 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 abstract 1
229960003437 aminoglutethimide Drugs 0.000 abstract 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 abstract 1
229960002932 anastrozole Drugs 0.000 abstract 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 abstract 1
PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 abstract 1
229950004810 atamestane Drugs 0.000 abstract 1
229960000255 exemestane Drugs 0.000 abstract 1
229950011548 fadrozole Drugs 0.000 abstract 1
SLJZVZKQYSKYNV-ZWKOTPCHSA-N finrozole Chemical compound C([C@H](O)[C@@H](C=1C=CC(=CC=1)C#N)N1N=CN=C1)C1=CC=C(F)C=C1 SLJZVZKQYSKYNV-ZWKOTPCHSA-N 0.000 abstract 1
229950001083 finrozole Drugs 0.000 abstract 1
229960004421 formestane Drugs 0.000 abstract 1
OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 abstract 1
GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 abstract 1
229960003881 letrozole Drugs 0.000 abstract 1
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 abstract 1
229960001771 vorozole Drugs 0.000 abstract 1
XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Child & Adolescent Psychology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW095114529A 2005-04-25 2006-04-24 Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor TW200716094A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US67480705P	2005-04-25	2005-04-25

Publications (1)

Publication Number	Publication Date
TW200716094A true TW200716094A (en)	2007-05-01

Family

ID=36693972

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095114529A TW200716094A (en)	2005-04-25	2006-04-24	Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor

Country Status (6)

Country	Link
EP (1)	EP1937251A2 (fr)
JP (1)	JP2006306872A (fr)
AR (1)	AR054258A1 (fr)
CA (1)	CA2605796A1 (fr)
TW (1)	TW200716094A (fr)
WO (1)	WO2006114702A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0711525A2 (pt)	2006-06-02	2011-11-01	Pear Tree Women S Health Care	composição farmacêutica e método para tratar sintomas de vaginite atrófica
EP2070943A1 (fr) *	2007-12-14	2009-06-17	Crystal Pharma, S.A.	Procédé de préparation des 6-Alkylidenandrost-1,4-dien-3-ones
JP5777163B2 (ja) *	2009-07-03	2015-09-09	国立研究開発法人理化学研究所	Ｐｅｔ用標識化合物
PT2753312T (pt) *	2011-09-08	2017-02-03	Mereo Biopharma 2 Ltd	Utilização de um inibidor da aromatase para o tratamento de hipogonadismo e doenças relacionadas
JP7131773B2 (ja) *	2016-04-29	2022-09-06	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	ホルモン受容体に関連する転写活性の標的尺度

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5552412A (en) *	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
AR034142A1 (es) *	2000-09-08	2004-02-04	Sloan Kettering Inst Cancer	Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
NZ524104A (en) *	2000-09-08	2004-12-24	Pharmacia Italia S	Exemestane as chemopreventing agent
WO2003017973A1 (fr) *	2001-08-31	2003-03-06	Pantarhei Bioscience B.V.	Traitement de troubles gynecologiques benins et vecteur d'administration a cet effet
EP1435967A2 (fr) *	2001-10-10	2004-07-14	Pharmacia Italia S.p.A.	Procedes de prevention et de traitement de la deperdition osseuse avec des composes steroides
WO2005070434A2 (fr) *	2004-01-13	2005-08-04	Wyeth	Traitement de l'osteoporose liee a la therapie par un inhibiteur de l'aromatase
WO2006048749A1 (fr) *	2004-11-04	2006-05-11	Pfizer Products Inc.	Anticorps ctla-4 et inhibiteur de l'aromatase ou traitement combine du cancer du sein

2006
- 2006-04-13 EP EP06744583A patent/EP1937251A2/fr not_active Withdrawn
- 2006-04-13 WO PCT/IB2006/001040 patent/WO2006114702A2/fr not_active Ceased
- 2006-04-13 CA CA002605796A patent/CA2605796A1/fr not_active Abandoned
- 2006-04-24 JP JP2006118713A patent/JP2006306872A/ja active Pending
- 2006-04-24 AR AR20060101616A patent/AR054258A1/es not_active Application Discontinuation
- 2006-04-24 TW TW095114529A patent/TW200716094A/zh unknown

Also Published As

Publication number	Publication date
CA2605796A1 (fr)	2006-11-02
WO2006114702A2 (fr)	2006-11-02
JP2006306872A (ja)	2006-11-09
EP1937251A2 (fr)	2008-07-02
WO2006114702A3 (fr)	2007-01-04
AR054258A1 (es)	2007-06-13

Publication	Publication Date	Title
ATE504565T1 (de)	2011-04-15	Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
JP2010521483A5 (fr)	2011-04-14
CY1109860T1 (el)	2014-09-10	Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
GEP20115213B (en)	2011-05-10	Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
TW200624427A (en)	2006-07-16	Heterocyclic derivatives and their use as therapeutic agents
NZ593593A (en)	2013-11-29	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TW200626148A (en)	2006-08-01	Heterocyclic derivatives and their use as therapeutic agents
MX2024001849A (es)	2024-02-29	Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
TW200626139A (en)	2006-08-01	Heterocyclic derivatives and their use as therapeutic agents
ATE371656T1 (de)	2007-09-15	Heteroaryl-pyrimidinderivate als jak-inhibitoren
TW200626592A (en)	2006-08-01	Heterocyclic derivatives and their use as therapeutic agents
TW200626155A (en)	2006-08-01	Heterocyclic derivatives and their use as therapeutic agents
EE200300403A (et)	2003-12-15	N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
UA86957C2 (ru)	2009-06-10	Производные азепиноиндола в качестве фармацевтического средства
MX2007003321A (es)	2007-06-05	Derivados heterociclicos y su uso como agentes terapeuticos.
UA84146C2 (ru)	2008-09-25	Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний
CA2484188A1 (fr)	2003-11-06	Antagonistes du recepteur tachykinine
NO20070224L (no)	2007-04-02	2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20054905L (no)	2006-01-25	2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
CA2409741A1 (fr)	2001-12-06	Inhibiteurs de production de tnf-.alpha.
ATE384058T1 (de)	2008-02-15	Thiazolderivate
ATE522526T1 (de)	2011-09-15	4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen
NO20056192L (no)	2005-12-27	Kapaseinhibitorer og anvendelse derav
WO2005030187A3 (fr)	2005-06-23	Iloprost en polytherapies pour le traitement de l'hypertension arterielle pulmonaire
MXPA03010054A (es)	2004-04-02	Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.